Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report

Kenta Kawasaki, Yasuo Hamamoto, Masayuki Adachi, Takanori Kanai, Hiromasa Takaishi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity.

Original languageEnglish
Pages (from-to)231-233
Number of pages3
JournalOncology Letters
Volume11
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Colorectal Neoplasms
Lung
Neoplasm Metastasis
Neoplasms
Angiogenesis Inhibitors
Carcinoembryonic Antigen
Differentiation Antigens
Neoplasm Antigens
Pneumothorax
Tumor Biomarkers
Protein-Tyrosine Kinases
Lung Neoplasms
Hemorrhage
regorafenib
Liver
Serum
Therapeutics

Keywords

  • Cavity formation
  • Colorectal cancer
  • Lung metastasis
  • Regorafenib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Early tumor cavitation with regorafenib in metastatic colorectal cancer : A case report. / Kawasaki, Kenta; Hamamoto, Yasuo; Adachi, Masayuki; Kanai, Takanori; Takaishi, Hiromasa.

In: Oncology Letters, Vol. 11, No. 1, 01.01.2016, p. 231-233.

Research output: Contribution to journalArticle

@article{a8dfdb40690745b6a89b232ca5efa88f,
title = "Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report",
abstract = "Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38{\%}, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity.",
keywords = "Cavity formation, Colorectal cancer, Lung metastasis, Regorafenib",
author = "Kenta Kawasaki and Yasuo Hamamoto and Masayuki Adachi and Takanori Kanai and Hiromasa Takaishi",
year = "2016",
month = "1",
day = "1",
doi = "10.3892/ol.2015.3905",
language = "English",
volume = "11",
pages = "231--233",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Early tumor cavitation with regorafenib in metastatic colorectal cancer

T2 - A case report

AU - Kawasaki, Kenta

AU - Hamamoto, Yasuo

AU - Adachi, Masayuki

AU - Kanai, Takanori

AU - Takaishi, Hiromasa

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity.

AB - Tumoral cavity formation is a characteristic phenomenon reported in anti-angiogenic therapy in lung lesions. A 57-year-old male with multiple pulmonary metastases from colorectal cancer treated with an oral tyrosine kinase inhibitor, regorafenib, exhibited a characteristic cavity formation after the first two cycles. The decrease in the size of tumors was calculated as 38%, and there were associated decreases in the serum concentrations of the tumor markers carcinoembryonic antigen and CA19-9. After eight cycles of treatment, the cavity gradually disappeared through filling-in. This unique morphological response is not only reported in lung cancer but also in liver metastasis in colorectal cancer. However, the association between morphological changes including cavity formation and clinical benefit remains controversial. Pulmonary hemorrhage and pneumothorax are well-known consequences of cavitation, as reported with the other anti-angiogenic inhibitors. Early tumor cavitation in lung metastasis may demonstrate the predictive potential of regorafenib in colorectal cancer, although it is necessary to be mindful of toxicity.

KW - Cavity formation

KW - Colorectal cancer

KW - Lung metastasis

KW - Regorafenib

UR - http://www.scopus.com/inward/record.url?scp=84948772839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948772839&partnerID=8YFLogxK

U2 - 10.3892/ol.2015.3905

DO - 10.3892/ol.2015.3905

M3 - Article

AN - SCOPUS:84948772839

VL - 11

SP - 231

EP - 233

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -